All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Cytrx Corp.'s decision to stop in May its Phase IIb trial with the synthetic retinoid tamibarotene for non-small-cell lung cancer turned investor eyes to aldoxorubicin, an improved, albumin-binding form of the chemotherapy drug doxorubicin at the same stage of testing in first-line soft-tissue sarcoma (STS).